Luciana Vinti, MD, IRCCS Bambino Gesù Children's Hospital, Rome, Italy, provides an update on the Phase II KEYNOTE-667 trial (NCT03407144), which is evaluating the safety and efficacy of pembrolizumab in children and young adults with classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy. Dr Vinti shares results from the trial, highlighting the percentage of patients who obtained PET negativity following consolidation with pembrolizumab plus cyclophosphamide, vincristine, prednisone and dacarbazine (COPDAC-28) chemotherapy. These results demonstrate that treatment using pembrolizumab plus COPDAC-28 chemotherapy may increase the likelihood of avoiding radiotherapy when treating patients in this setting. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
